SCHEMBL7121392

SCHEMBL7121392

CCCc1c(O)c2cc(F)ccc2[nH]c1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.65
ALDH1A1 P00352 6/20 0.65
HPGD P15428 4/20 0.65
HSD17B10 Q99714 5/20 0.55
GAA P10253 1/20 0.53
TSHR P16473 1/20 0.52
GSK3B P49841 1/20 0.51
GHSR Q92847 1/20 0.48
RAB9A P51151 1/20 0.48
MAPT P10636 2/20 0.46
HTT P42858 1/20 0.46
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
DAO P14920 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MPO P05164 2/20 0.44
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7122354 0.88 KDM5A (0.54) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL7120420 0.84 HSD17B10 (0.74) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL17505210 0.83 ALDH1A1 (0.65) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL7117408 0.83 ALDH1A1 (0.65) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL7116460 0.83 ALDH1A1 (0.65) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL7124017 0.82 KDM4E (0.46) KDM4EALDH1A1HPGDHSD17B10GSK3B
SCHEMBL7119124 0.81 ALDH1A1 (0.62) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL7123404 0.80 MEN1 (0.61) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL7119311 0.79 KDM4E (0.56) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL5307307 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 KDM4E 3240/4885ALDH1A1 1742/4885HPGD 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.